Cömert Duygu Kavak, Üreyen Işın, Karalok Alper, Taşçı Tolga, Türkmen Osman, Öcalan Reyhan, Turan Taner, Tulunay Gökhan
Department of Obstetrics and Gynecology, Ankara Training and Research Hospital, Ankara, Turkey.
Department of Obstetrics and Gynecology, Etlik Zübeyde Hanım Women's Health Training and Research Hospital, Ankara, Turkey.
J Turk Ger Gynecol Assoc. 2016 Jan 12;17(2):96-100. doi: 10.5152/jtgga.2016.15208. eCollection 2016.
To analyze the clinicopathologic features, recurrence and survival rates, reproductive history, and treatment of patients with mucinous borderline ovarian tumors (mBOTs).
Patients with a diagnosis of mBOT were evaluated retrospectively. Patients with borderline ovarian tumors other than mucinous type and concomitant invasive cancer were excluded.
A total of 75 patients were identified. Median age was 38 years. The most common symptom was pain (42.7%). Median CA-125 level was 23.5 IU/mL (range, 1-809 IU/mL). Median tumor size was 200 mm (range, 40-400 mm), and 6.7% of mBOTs were bilateral. Thirty-six (48%) patients underwent staging surgery. Two patients (5.9%) had nodal involvement. One patient received platinum-based adjuvant chemotherapy. One (1.3%) patient had recurrence. None of the patients died because of the ovarian tumor. A total of 43 patients had conservative surgery.
Prognosis of mBOTs is excellent, and fertility-sparing surgery should be considered in the reproductive age group. Furthermore, the necessity of staging surgery is controversial.
分析黏液性交界性卵巢肿瘤（mBOTs）患者的临床病理特征、复发率和生存率、生育史及治疗情况。
对诊断为mBOTs的患者进行回顾性评估。排除黏液性以外的其他类型交界性卵巢肿瘤及合并浸润性癌的患者。
共纳入75例患者。中位年龄为38岁。最常见症状为疼痛（42.7%）。CA-125中位水平为23.5 IU/mL（范围1 - 809 IU/mL）。肿瘤中位大小为200 mm（范围40 - 400 mm），6.7%的mBOTs为双侧性。36例（48%）患者接受了分期手术。2例（5.9%）患者有淋巴结受累。1例患者接受了铂类辅助化疗。1例（1.3%）患者复发。无患者因卵巢肿瘤死亡。共43例患者接受了保留生育功能手术。
mBOTs预后良好，生育年龄组患者应考虑保留生育功能手术。此外，分期手术的必要性存在争议。
